Impact of CDKN2A/B, MTAP, and TERT Genetic Alterations on Survival in IDH Wild Type Glioblastomas

por Hsu, Eric J., Thomas, Jamie, Maher, Elizabeth A., Youssef, Michael, Timmerman, Robert D., Wardak, Zabi, Dan, Tu D., Patel, Toral R., Vo, Dat T.
Publicado 2022

Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients

por Hsu, Eric J., Thomas, Jamie, Maher, Elizabeth A., Youssef, Michael, Timmerman, Robert D., Wardak, Zabi, Lee, Minjae, Dan, Tu D., Patel, Toral R., Vo, Dat T.
Publicado 2022

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients

por Choi, Changho, Ganji, Sandeep K., DeBerardinis, Ralph J., Hatanpaa, Kimmo J., Rakheja, Dinesh, Kovacs, Zoltan, Yang, Xiao-Li, Mashimo, Tomoyuki, Raisanen, Jack M., Marin-Valencia, Isaac, Pascual, Juan M., Madden, Christopher J., Mickey, Bruce E., Malloy, Craig M., Bachoo, Robert, Maher, Elizabeth A.
Publicado 2012

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

por Mellinghoff, Ingo K., Lu, Min, Wen, Patrick Y., Taylor, Jennie W., Maher, Elizabeth A., Arrillaga-Romany, Isabel, Peters, Katherine B., Ellingson, Benjamin M., Rosenblum, Marc K., Chun, Saewon, Le, Kha, Tassinari, Ania, Choe, Sung, Toubouti, Youssef, Schoenfeld, Steven, Pandya, Shuchi S., Hassan, Islam, Steelman, Lori, Clarke, Jennifer L., Cloughesy, Timothy F.
Publicado 2023

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

por Mellinghoff, Ingo K., Penas-Prado, Marta, Peters, Katherine B., Burris, Howard A., Maher, Elizabeth A., Janku, Filip, Cote, Gregory M., de la Fuente, Macarena I., Clarke, Jennifer L., Ellingson, Benjamin M., Chun, Saewon, Young, Robert J., Liu, Hua, Choe, Sung, Lu, Min, Le, Kha, Hassan, Islam, Steelman, Lori, Pandya, Shuchi S., Cloughesy, Timothy F., Wen, Patrick Y.
Publicado 2021